DIVI S LABORATORIES LTD vs Venmax Drugs & Pharmaceuticals Ltd

A side-by-side comparison of DIVI S LABORATORIES LTD (DIVISLAB) and Venmax Drugs & Pharmaceuticals Ltd (VENMAXDRUGSPHARMACEUTICALSLTD) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, DIVI S LABORATORIES LTD leads DIVISLAB vs VENMAXDRUGSPHARMACEUTICALSLTD on 12 of 14 metrics (1 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

74.93
P/E ratio
92.20
10.72
P/B ratio
1.59
0.44%
Dividend yield
0.00%
₹96.73
EPS
₹-0.02

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

16.50%
Return on equity
2.70%
22.00%
Return on capital
5.29%
33.00%
EBITDA margin
-114.81%
24.32%
Net margin
-1.23%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y)
12.10%
Profit CAGR (3Y)
2.82%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.92L Cr
Market cap
₹23 Cr
₹10,560 Cr
Revenue
₹1 Cr
₹2,568 Cr
Net profit
₹-0 Cr
0.00
Debt / equity
0.02
DIVI S LABORATORIES LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 10.8 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
Venmax Drugs & Pharmaceuticals Ltd
  • + ["Company is almost debt free.", "Debtor days have improved from 247 to 65.1 days."]
  • ["Promoter holding has decreased over last quarter: -1.34%", "Promoter holding is low: 13.8%"]
DIVI S LABORATORIES LTD full analysis Venmax Drugs & Pharmaceuticals Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.